‌

US Patent 9474780 GIP and GLP-1 co-agonist compounds

Patent 9474780 was granted and assigned to Eli Lilly and Company on October, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Current Assignee

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Robert Chadwick Cummins3

Bengt Krister Bokvist3

Jorge Alsina-Fernandez3

Tamer Coskun3

Date of Patent

October 25, 2016

Patent Application Number

14987791

Date Filed

January 5, 2016

Patent Citations Received

US Patent 11918623 GIP/GLP1 agonist compositions

1

US Patent 11865160 Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

2

Patent Primary Examiner

Christina Bradley

Patent abstract

The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9474780 GIP and GLP-1 co-agonist compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.